Navigation Links
Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
Date:10/24/2013

Geneva, Switzerland (PRWEB) October 24, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Improved Recombinant Protein Production” on Tuesday, November 5 at 4:45 PM at the BIO-Europe 2013 Partnering Conference being held November 4 – 6, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Stable, high-level production of recombinant proteins requires not only elevated transcription, but also cellular systems that can accommodate all of the protein folding, metabolic, secretory transport and post-translational processing requirements of any given protein. These requirements can vary significantly from protein to protein. Leveraging data from the completed SURE CHO-M Genome and Transciptome, Selexis has engineered the SURE CHO-Mplus libraries to address expression issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration. With these libraries, Selexis has been able to significantly boost expression over broad range of proteins, including large multimeric structural proteins and and difficult to express proteins.

Companies or individuals attending BIO-Europe can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bioeurope/index.php

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #

Read the full story at http://www.prweb.com/releases/selexis_bio_europe/protiens_antibodies/prweb11264432.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Targeted therapeutics for colon cancer to be presented at AACR meeting
9. NYU Langone experts present research, clinical advances at neurosurgeons meeting
10. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
11. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Christmas in Suffolk”: ... of published author, Sara Seymour, who lives in Lafayette, Indiana where she works in ... on iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new ...
(Date:1/19/2017)... , ... January 20, 2017 , ... Today, the Centers ... participate in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate ... APMs are an important part of the Administration’s effort to build a system ...
(Date:1/19/2017)... , ... January 19, 2017 , ... This month, the ... that the name of their drug rehab center in Delray Beach, Florida has been ... that not only stars such as Philip Seymour Hoffman and Chris Farley are dying ...
(Date:1/19/2017)... ... 19, 2017 , ... WholeHealth is announcing their participation in ... Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in the ... , “We know it’s easy to get carried away when you’re having ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 20, 2017 Research and Markets has ... (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, ... offering. ... Global Hearing Aids Market Sales Volume, Company Analysis and Forecast ... hearing aid industry. The growing prevalence of hearing ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com ... (NASDAQ: SGYP ), Novo Nordisk A/S (NYSE: ... ), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX ... on Thursday, January 19 th , 2017, finishing near its ... Care Index dropped over 0.7%, while shares of health care ...
(Date:1/20/2017)...  Palladian Health, a leading provider of quality ... an opioid management program which assists physicians in ... stem the growing tide of dependence on prescription ... non-cancer pain (back pain, neck pain, and degenerative ... evidence regarding long-term effectiveness. The new ...
Breaking Medicine Technology: